Bismuth Drugs Reverse Tet(X)-Conferred Tigecycline Resistance in Gram-Negative Bacteria | Zendy

Tian Deng | Zendy; Yuqian Jia | Zendy; Ziwen Tong | Zendy; Jingru Shi | Zendy; Zhiqiang Wang | Zendy; Yuan Liu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bismuth Drugs Reverse Tet(X)-Conferred Tigecycline Resistance in Gram-Negative Bacteria

Author(s) -

Tian Deng,

Yuqian Jia,

Ziwen Tong,

Jingru Shi,

Zhiqiang Wang,

Yuan Liu

Publication year - 2022

Publication title -

microbiology spectrum

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.502

H-Index - 51

ISSN - 2165-0497

DOI - 10.1128/spectrum.01578-21

Subject(s) - tigecycline , antibiotics , antimicrobial , microbiology and biotechnology , efflux , bacteria , antibiotic resistance , multiple drug resistance , biology , drug resistance , pharmacology , chemistry , biochemistry , genetics

Recently, high-level tigecycline resistance mediated bytet (X4) and its variants represents a serious challenge for global public health. Antibiotic adjuvant strategy that enhances the activity of the existing antibiotics by using nonantibiotic drugs offers a distinct approach to combat the antibiotic resistance crisis. In this study, we found that bismuth drugs involve bismuth nitrate, a compound previously approved for treatment of stomach-associated diseases, remarkably potentiates tigecycline activity againsttet (X)-positive bacteria.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research